Lisaftoclax launched as China's first Bcl-2 inhibitor in CLL/SLL; the thesis turns on NRDL inclusion and commercial ramp against venetoclax's global dominance

Bull

Successful NRDL inclusion would dramatically expand patient access by reducing out-of-pocket costs, replicating the trajectory seen with olverembatinib, which grew revenue 81% year-over-year following its own NRDL expansion in January 2025. A favorable price negotiation that preserves meaningful unit economics while driving volume would validate the commercial model and establish lisaftoclax as the standard-of-care Bcl-2 inhibitor in relapsed/refractory CLL/SLL in China ahead of any potential venetoclax entry.

Bear

The primary failure mode is a steep price cut demanded during NRDL negotiation that compresses margins to the point where revenue growth fails to offset the company's rising cost base, as occurred with many oncology agents in China's annual NRDL cycles. A second risk is outright exclusion or deferral to a later negotiation round, which would leave lisaftoclax dependent on a narrow out-of-pocket paying population and make the $10.1 million five-month launch revenue figure a ceiling rather than a floor.